Transcutaneous bilirubin levels in extremely preterm infants less than 30 weeks gestation

Meera N Sankar1, Rangasamy Ramanathan2, Priscilla Joe3

  • 1Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University, Stanford, CA, USA. mnsankar@stanford.edu.

Insights

Transcutaneous bilirubin (TcB) effectively screens jaundice in extremely preterm infants. This non-invasive method correlates well with total serum bilirubin (TSB) levels, aiding clinical decisions.

Area of Science:

  • Neonatal Medicine
  • Pediatric Endocrinology

Background:

  • Jaundice is common in preterm infants.
  • Accurate bilirubin monitoring is crucial for preventing complications.

Purpose of the Study:

  • To assess the correlation between transcutaneous bilirubin (TcB) and total serum bilirubin (TSB) levels.
  • To evaluate TcB as a screening tool in extremely preterm infants.

Main Methods:

  • Prospective multicenter study.
  • Inclusion of infants <30 weeks gestation.
  • Comparison of paired TcB and TSB values across various infant characteristics and treatment phases.

Main Results:

  • TSB values ranged from 0 to 12.6 mg/dl; TcB values ranged from 0 to 14.2 mg/dl.
  • High accuracy in predicting TSB from TcB (TSB = 2.37 + 0.54 * TcB, r = 0.786).
  • Good correlation observed across subgroups (gestational age, birth weight, race/ethnicity, age) and during/after phototherapy.

Conclusions:

  • TcB is a reliable non-invasive screening tool for jaundice in extremely preterm infants.
  • Supports the use of TcB for routine jaundice monitoring in this vulnerable population.
Abstract